Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Shares Outstanding (Weighted Average) (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Shares Outstanding (Weighted Average) readings, the most recent being $22.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.23% to $22.9 million in Q1 2026 year-over-year; TTM through Jan 2026 was $22.9 million, a 0.23% change, with the full-year FY2025 number at $22.9 million, changed 0.08% from a year prior.
  • Shares Outstanding (Weighted Average) hit $22.9 million in Q1 2026 for Pharma-Bio Serv, roughly flat from $22.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $23.0 million in Q4 2022 to a low of $22.9 million in Q1 2026.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $23.0 million (2024), compared with a mean of $23.0 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): dropped 0.34% in 2022 and later rose 0.08% in 2024.
  • Pharma-Bio Serv's Shares Outstanding (Weighted Average) stood at $23.0 million in 2022, then dropped by 0.14% to $23.0 million in 2023, then dropped by 0.02% to $23.0 million in 2024, then dropped by 0.08% to $22.9 million in 2025, then dropped by 0.18% to $22.9 million in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $22.9 million (Q1 2026), $22.9 million (Q4 2025), and $22.9 million (Q3 2025) per Business Quant data.